{
  "docId": "019de514-f120-743f-9d00-70915b7d1fa5",
  "docSlug": "a9055659e75fd1b92a3c529616eb6953",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 49 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 49,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-f120-743f-9d00-70915b7d1fa5/25",
  "deckHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5",
  "deckJsonHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5.json",
  "deckAnchorHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.24,
        "w": 0.34,
        "x": 0.569,
        "y": 0.64
      },
      "kind": "chart",
      "text": "Ocular Dryness² (ITT³)\nDecrease from Baseline (%)\nN=311 -45.4%\nN=309 -29.8%\np<0.001\nNOV03 Saline",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cecc640-78fa-4c09-be4b-f314488156fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.24,
        "w": 0.34,
        "x": 0.569,
        "y": 0.309
      },
      "kind": "chart",
      "text": "Total Corneal Staining² (ITT³)\nDecrease from Baseline (%)\nN=311 -33.3%\nN=309 -15.8%\np<0.001\nNOV03 Saline",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e2d103a-7f95-485e-b047-b930fa96be76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.104,
        "x": 0.329,
        "y": 0.783
      },
      "kind": "metric",
      "text": "Expect Double\nDigit Growth\n2021-20275,6",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b7b221b-a9be-4326-a888-08bae721d17c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.09,
        "x": 0.143,
        "y": 0.783
      },
      "kind": "metric",
      "text": "~24% CAGR\n2016-20214",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79a47ed6-a7b1-4606-b60c-0e15cc3f7148",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.379,
        "x": 0.099,
        "y": 0.192
      },
      "kind": "paragraph",
      "text": "Pivotal Phase 3 Trial GOBI Data on\nNOV03 Now Published in Ophthalmology",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51f2102d-b92c-4ee0-a771-09f96d2a743b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.317,
        "x": 0.172,
        "y": 0.519
      },
      "kind": "paragraph",
      "text": "Statistically significant difference of sign and\nsymptom was noted at day 15 and 57 in both Phase 3\nstudies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76c19fc8-ad61-477b-807d-3fab79aec657",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.359,
        "x": 0.101,
        "y": 0.704
      },
      "kind": "paragraph",
      "text": "U.S. Prescription Dry Eye Market Growth",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab1328cf-5d40-4302-9d65-d7b0a75b7e58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.317,
        "x": 0.172,
        "y": 0.299
      },
      "kind": "paragraph",
      "text": "Investigational first in class treatment for Dry Eye\nDisease (DED) associated with Meibomian Gland\nDysfunction (MGD)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab8fc7b6-fb74-4d06-af03-c6e76682d280",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.249,
        "x": 0.172,
        "y": 0.63
      },
      "kind": "paragraph",
      "text": "Canadian Filing Expected 1Q236",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c95a2bab-28e3-4b1a-bf34-ebbc1edfd274",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.317,
        "x": 0.172,
        "y": 0.409
      },
      "kind": "paragraph",
      "text": "Consistent statistically significant efficacy, safety and\ntolerability have now been demonstrated in two Phase 3\nstudies of NOV03¹ and one Phase 2 study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f58ba460-1bb0-4928-994a-ef43cc56e70b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.36,
        "x": 0.569,
        "y": 0.177
      },
      "kind": "paragraph",
      "text": "Second Phase 3 (MOJAVE) Efficacy Endpoints:\nTotal Corneal Staining (sign) and\nOcular Dryness (symptom) at Day 57",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f83d7352-8980-478b-93f6-2144de4f9c23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.775,
        "x": 0.158,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.\n2. P-value for the difference in Least Squared Means.\n3. Intent-to-treat.\n4. IQVIA NSP.\n5. Clarivate\n6. See Slide 1 for further information on forward-looking statements.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71ccac16-e711-4e68-a434-b71090a06172",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.409,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "NOV031: PDUFA Date June 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f632a9f1-57b3-423d-b7d3-63f42d78837e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 27,
      "from": 21,
      "beatId": "af07aa86-1701-4c73-96c4-171c7b6c54df",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with a call to action, highlighting growth opportunities and future prospects",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}